» Articles » PMID: 35936744

Tumor Microbiome Metabolism: A Game Changer in Cancer Development and Therapy

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 8
PMID 35936744
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating recent evidence indicates that the human microbiome plays essential roles in pathophysiological states, including cancer. The tumor microbiome, an emerging concept that has not yet been clearly defined, has been proven to influence both cancer development and therapy through complex mechanisms. Small molecule metabolites produced by the tumor microbiome through unique biosynthetic pathways can easily diffuse into tissues and penetrate cell membranes through transporters or free diffusion, thus remodeling the signaling pathways of cancer and immune cells by interacting with biomacromolecules. Targeting tumor microbiome metabolism could offer a novel perspective for not only understanding cancer progression but also developing new strategies for the treatment of multiple cancer types. Here, we summarize recent advances regarding the role the tumor microbiome plays as a game changer in cancer biology. Specifically, the metabolites produced by the tumor microbiome and their potential effects on the cancer development therapy are discussed to understand the importance of the microbial metabolism in the tumor microenvironment. Finally, new anticancer therapeutic strategies that target tumor microbiome metabolism are reviewed and proposed to provide new insights in clinical applications.

Citing Articles

The bacterial microbiome modulates the initiation of brain metastasis by impacting the gut-to-brain axis.

Massara M, Ballabio M, Dolfi B, Morad G, Wischnewski V, Lamprou E iScience. 2025; 28(2):111874.

PMID: 39995854 PMC: 11848439. DOI: 10.1016/j.isci.2025.111874.


Post-Translational Modifications of Proteins Orchestrate All Hallmarks of Cancer.

Bruno P, Arshad A, Gogu M, Waterman N, Flack R, Dunn K Life (Basel). 2025; 15(1).

PMID: 39860065 PMC: 11766951. DOI: 10.3390/life15010126.


Effect of Gut Dysbiosis on Onset of GI Cancers.

Kumari S, Srilatha M, Nagaraju G Cancers (Basel). 2025; 17(1.

PMID: 39796717 PMC: 11720164. DOI: 10.3390/cancers17010090.


Impact of Metabolites from Foodborne Pathogens on Cancer.

Mafe A, Busselberg D Foods. 2024; 13(23).

PMID: 39682958 PMC: 11640045. DOI: 10.3390/foods13233886.


Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response.

Zhang H, Fu L, Leiliang X, Qu C, Wu W, Wen R Cancer Commun (Lond). 2024; 44(10):1130-1167.

PMID: 39087354 PMC: 11483591. DOI: 10.1002/cac2.12597.


References
1.
Mirzaei R, Afaghi A, Babakhani S, Sohrabi M, Hosseini-Fard S, Babolhavaeji K . Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother. 2021; 139:111619. DOI: 10.1016/j.biopha.2021.111619. View

2.
Liu Y, Li Z, Wu Y, Jing X, Li L, Fang X . Intestinal Bacteria Encapsulated by Biomaterials Enhance Immunotherapy. Front Immunol. 2021; 11:620170. PMC: 7902919. DOI: 10.3389/fimmu.2020.620170. View

3.
Huang T, Lai J, Du Y, Xu Y, Ruan L, Hu S . Current Understanding of Gut Microbiota in Mood Disorders: An Update of Human Studies. Front Genet. 2019; 10:98. PMC: 6389720. DOI: 10.3389/fgene.2019.00098. View

4.
Yang W, Yu T, Huang X, Bilotta A, Xu L, Lu Y . Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. Nat Commun. 2020; 11(1):4457. PMC: 7478978. DOI: 10.1038/s41467-020-18262-6. View

5.
Pan H, Zheng M, Ma A, Liu L, Cai L . Cell/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy. Adv Mater. 2021; 33(50):e2100241. DOI: 10.1002/adma.202100241. View